Clinical Trials Browser

Phase 2 × Carcinoma, Transitional Cell × cabozantinib × Clear all

NCT03866382 2026-05-26

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT03534804 2024-11-26

PemCab

Phase 2 Completed

37 enrolled 27 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT01688999 2022-10-18

Cabozantinib for Advanced Urothelial Cancer

Phase 2 Completed

69 enrolled 14 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Urethral Neoplasms

NCT04066595 2021-08-30

CabUC

Phase 2 Terminated

7 enrolled

Genitourinary

Carcinoma, Transitional Cell